文献速递神经肿瘤

现代分子分型重新解读NRG/RTOG 0539试验并揭示隐藏的高危及放疗抵抗脑膜瘤

Modern molecular profiling recontextualizes the NRG/RTOG 0539 trial and reveals hidden high-risk and radiotherapy-resistant meningiomas.
PubMed 文献 · Neuro Oncol · 2026-01-01

该研究对NRG/RTOG-0539试验中100例脑膜瘤患者肿瘤组织行DNA甲基化阵列、RNA测序及全外显子测序,发现整合分子与细胞遗传学特征的现代分级标准可重新分类10%肿瘤并改变7%患者的治疗分组;增殖性分子亚组是放疗后复发的独立预测因子,优于WHO分级。

要点

  • 现代分级标准(含脑侵犯、TERT突变、CDKN2A/B缺失、1p/1q状态)可重新分类10%肿瘤并改变7%治疗分组。
  • 放疗无应答者更常见1p和14q缺失及更多拷贝数变异,转录组与表观遗传谱显示应答者免疫相关特征、无应答者细胞周期相关通路。
  • 增殖性分子亚组是多变量分析中放疗后复发的独立预测因子,优于WHO分级。

核心结论

  • 整合分子与细胞遗传学特征的更新WHO分级标准可改善脑膜瘤风险分层。
  • 分子分型尤其是增殖性组仍是放疗应答的独立且更强预测因子,支持将分子生物标志物与现代分级框架结合以指导治疗和试验设计。

研究设计与样本

  • 对NRG/RTOG-0539前瞻性2期试验中100例脑膜瘤患者的肿瘤组织行DNA甲基化阵列、RNA测序和全外显子测序分析。
  • 比较临床分组间及放疗应答者与无应答者(定义为3年内进展或死亡)的复发评分、分子分组、基因表达和拷贝数变异。

主要发现

  • 现代分级标准(含脑侵犯、TERT突变、CDKN2A/B缺失及1p/1q状态)将重新分类10%肿瘤并改变7%患者的治疗分组。
  • 放疗无应答者更频繁出现1p和14q缺失及更多拷贝数变异。
  • 转录组和表观遗传分析显示应答者免疫相关特征、无应答者细胞周期相关通路,部分与伏立诺他(组蛋白去乙酰化酶抑制剂)靶点重叠。
  • 增殖性分子组在多变量分析中是放疗后复发的独立预测因子,优于WHO分级。

临床怎么用

  • 对脑膜瘤患者可考虑整合分子与细胞遗传学特征(如TERT突变、CDKN2A/B缺失、1p/1q状态)以改进风险分层。
  • 分子分型尤其是增殖性组有助于预测放疗应答和复发风险,可辅助治疗决策和临床试验设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Meningiomas exhibit clinical heterogeneity. Radiotherapy (RT) remains the only adjuvant therapy, but tumor-control is variable, and biomarkers are limited. NRG/RTOG-0539 is the first prospective phase 2 trial to stratify meningioma patients for adjuvant RT based on clinical risk. Here, we apply modern molecular tools to this cohort and identify correlates of RT response. METHODS: Tumor tissue from 100 RTOG-0539 patients was profiled using DNA methylation arrays, RNA sequencing, and whole-exome sequencing. Recurrence scores, Molecular Groups, gene expression, and copy number alterations were compared across clinical groups and between RT responders and non-responders; non-response was defined as progression or death within 3 years. RESULTS: Modern grading criteria, including brain invasion, TERT mutation, CDKN2A/B deletion, and 1p/1q status, would reclassify 10% of tumors and alter treatment group assignment in 7%. Non-responders to RT exhibited more frequent 1p and 14q loss, and more copy number alterations. Transcriptomic and epigenetic profiling revealed immune-related signatures in responders and cell cycle-related pathways in non-responders, several of which overlapped with targets of vorinostat, a histone deacetylase inhibitor previously validated in aggressive meningioma models. The Proliferative Molecular Group was an independent predictor of post-RT recurrence in multivariable analysis, outperforming WHO grade. CONCLUSION: Multi-omic analysis of the NRG/RTOG-0539 cohort shows that updated WHO grading criteria, incorporating molecular and cytogenetic features, improve risk stratification. However, molecular classification, particularly the Proliferative group, remains an independent and stronger predictor of RT response. These findings support integrating molecular biomarkers alongside modern grading frameworks to guide treatment and trial design in meningioma. CLINICAL TRIAL INFORMATION: NCT00895622. Meningiomas are brain tumors that can behave very differently from one patient to another. After surgery, the main additional treatment available is radiation therapy, but it does not work equally well for everyone. Doctors currently have limited ways to predict which tumors will respond well to radiation. In this study, researchers analyzed tumor samples from 100 patients enrolled in the NRG/RTOG-0539 clinical trial, which assigned radiation treatment based on patients’ clinical risk. Using modern laboratory methods, they studied changes in the tumors’ DNA and examined which genes were more or less active. The goal was to find biological features linked to how well tumors respond to radiation. The researchers found that using updated tumor grading rules that include certain genetic features would change how about 10% of tumors are classified. In about 7% of patients, this could have changed which treatment group they were placed in. Tumors that did not respond well to radiation were more likely to have losses of specific parts of their chromosomes (called 1p and 14q) and to show a larger number of overall genetic changes. Tumors that responded better to radiation showed signs of stronger immune activity. In contrast, tumors that did not respond tended to show signs of faster cell growth. The researchers also identified a specific biological subtype of meningioma, called the Proliferative group, that was strongly linked to the risk of the tumor coming back after radiation. This group predicted recurrence better than the traditional tumor grading system currently used in clinical practice. Overall, the results suggest that testing tumors for these molecular features could help doctors better predict which patients are most likely to benefit from radiation therapy. These findings may also help guide future clinical trials and support the development of new treatments for more aggressive meningiomas.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Yefet LS, Landry AP, Rogers CL, et al. Modern molecular profiling recontextualizes the NRG/RTOG 0539 trial and reveals hidden high-risk and radiotherapy-resistant meningiomas. Neuro Oncol. 2026. PMID: 42143623. doi:10.1093/neuonc/noag081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。